VJHemOnc Podcast
The growing role of immunotherapy in the treatment of ALL & moving away from stem cell transplantation
Mar 10, 2023
Experts Arnon Nagler, MD and Maksim Mamonkin, PhD discuss the growing role of immunotherapy in the treatment of B-cell acute lymphoblastic leukemia (B-ALL). They explore the use of novel immunotherapies like CAR-T cells, antibody-drug conjugates, and monoclonal antibodies, as well as the possibility of moving away from stem cell transplantation. Topics covered include targeting CD7 in T-ALL, chemotherapy-free regimens, and the future of ALL treatment.
09:01
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Immunotherapy has revolutionized the treatment landscape for ALL, improving outcomes and challenging the role of stem cell transplantation in high-risk patients with comorbidities.
- CD7 is an excellent target in T-cell ALL, and CAR T-cell approaches targeting CD7 have shown good activity as a bridge to stem cell transplantation, potentially eliminating the need for transplantation in certain patients by combining immunotherapy with CAR T-cells.
Deep dives
The Role of Immunotherapy in ALL Treatment
Immunotherapy has revolutionized the treatment landscape for acute lymphoblastic leukemia (ALL), particularly in refractory cases. Novel immunotherapies such as monoclonal antibodies, bispecific T-cell engagers (BiTEs), and chimeric antigen receptor (CAR) T-cell therapies have shown promising results. These advancements have not only improved outcomes but have also challenged the role of stem cell transplantation in some high-risk patients with comorbidities.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
